{"id":"midazolam-mylan","safety":{"commonSideEffects":[{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Amnesia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Midazolam binds to GABA-A receptors and potentiates the effect of the inhibitory neurotransmitter GABA, leading to increased chloride ion influx and neuronal hyperpolarization. This results in depression of the central nervous system with sedative, anxiolytic, anticonvulsant, and muscle relaxant properties. The drug is commonly used for procedural sedation, preoperative anxiolysis, and acute seizure management.","oneSentence":"Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation, anxiolysis, and muscle relaxation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:15.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Procedural sedation and anxiolysis"},{"name":"Preoperative anxiolysis"},{"name":"Acute seizure management"},{"name":"Induction of general anesthesia"}]},"trialDetails":[{"nctId":"NCT02078336","phase":"PHASE4","title":"Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-12","conditions":"Dental Care for Disabled","enrollment":40},{"nctId":"NCT01517828","phase":"PHASE3","title":"Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room","status":"UNKNOWN","sponsor":"University Hospital, Montpellier","startDate":"2012-01","conditions":"Respiratory Distress Syndrome, Prematurity of Fetus","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Midazolam Mylan","genericName":"Midazolam Mylan","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Midazolam Mylan is a small molecule that acts as a positive allosteric modulator of the GABA-A receptor and anion channel. It has been studied for use in dental care for people with mental disability, as well as for conditions such as respiratory distress syndrome and prematurity of the fetus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}